|
2015 Sponsor |
AstraZeneca Korea |
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world¡¯s most serious illnesses: cardiovascular, cancer, gastrointestinal, infection.
Booth No. E006
|
Evening Symposium |
Risk Awareness of Secondary Events in Post MI Patients and Secondary Prevention |
Organized by CVRF and Supported by Educational Grant from Astrazeneca Korea |
Wednesday, April 29
6:00 PM - 8:00 PM
Room 104, Level 1 |
Moderator(s): Patrick W. Serruys, Ki-Bae Seung | Panelist(s): Jei Keon Chae, Kiyuk Chang, Hyeon-Cheol Gwon, Taek Jong Hong, Dong Woon Jeon, Cheol Whan Lee, Roxana Mehran, Freek W.A. Verheugt | |
6:00 PM |
Opening Remark (1)
Speaker : Ki-Bae Seung
|
6:05 PM |
Opening Remark (2)
Speaker : Patrick W. Serruys
|
6:10 PM |
Remnant Risk of Secondary MACE/ Mortality After Index AMI
Lecturer : Freek W.A. Verheugt
|
6:35 PM |
Remnant Risk of Secondary MACE/ Mortality After Index AMI in Asian Patients
Lecturer : Kiyuk Chang
|
7:00 PM |
Will Long Term Dual Antiplatelet Therapy Improve LT Outcome?
Lecturer : Roxana Mehran
|
7:25 PM |
Panel Discussion
|
7:55 PM |
Summary and Close
|
|
|
|
|
|
|
|
|
|
|
CardioVascular Research Foundation(CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
Tel: 82-2-3010-7255/ Business registration number: 215-82-06387
Copyright ¨Ï 2002 CVRF, Seoul, Korea. All rights reserved. |
|
|
|